This is read by an automated voice. Please report any issues or inconsistencies here. San Diego-based Avidity Biosciences Inc. agreed to be acquired by Novartis AG in a deal valued at $12 billion.

Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions "Avidity has expanded the possibilities of what RNA therapeutics can ...

SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...

Novartis has announced plans to acquire Avidity Biosciences for $12 billion in cash, marking one of the largest pharmaceutical deals of the year. The Swiss healthcare company is betting big on a new ...

Swiss drugmaker Novartis has agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, marking a major consolidation in the pharmaceutical sector as of October 26, 2025.

Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...